Parkinson's disease historical perspective
|
Parkinson's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parkinson's disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Parkinson's disease historical perspective |
|
Risk calculators and risk factors for Parkinson's disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Parkinson disease was first documented and recognized by a British physician, James Parkinson in 1817 who named it paralysis agitans. The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients. in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.
Historical Perspective
Discovery
- Parkinson disease was first documented and recognized by a British physician, James Parkinson in 1817 who named it paralysis agitans.[1]
- The current name of the disease (Parkinson disease) is from Jean-Martin Charcot.[2]
- The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients.
- Later on in 1919 Tretiakoff showed that in this patients’ substantia nigra there are evidences of neuronal loss.
- Finally in the 1950s dopamine depletion was known to be the underlying cause of the disease.[3]
- Later, in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.[4][5][6]
References
- ↑ Goetz, C. G. (2011). "The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies". Cold Spring Harbor Perspectives in Medicine. 1 (1): a008862–a008862. doi:10.1101/cshperspect.a008862. ISSN 2157-1422.
- ↑ Teive, Helio A. G.; Munhoz, Renato Puppi; Barbosa, Egberto Reis (2007). "Little-known scientific contributions of J-M Charcot". Clinics. 62 (3): 211–214. doi:10.1590/S1807-59322007000300003. ISSN 1807-5932.
- ↑ Hornykiewicz O (2006). "The discovery of dopamine deficiency in the parkinsonian brain". J. Neural Transm. Suppl. (70): 9–15. PMID 17017502.
- ↑ Manyam BV, Sánchez-Ramos JR (1999). "Traditional and complementary therapies in Parkinson's disease". Adv Neurol. 80: 565–74. PMID 10410773.
- ↑ Parkinson J (2002). "An essay on the shaking palsy. 1817". J Neuropsychiatry Clin Neurosci. 14 (2): 223–36, discussion 222. doi:10.1176/jnp.14.2.223. PMID 11983801.
- ↑ Hornykiewicz O (2002). "L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent". Amino Acids. 23 (1–3): 65–70. doi:10.1007/s00726-001-0111-9. PMID 12373520.<ref name="pmid5637779">Cotzias GC (March 1968). "L-Dopa for Parkinsonism". N. Engl. J. Med. 278 (11): 630. PMID 5637779.